Royce & Associates’s ANI Pharmaceuticals ANIP Stock Holding History

Royce & Associates’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	18,416 -5,635	-23%	-$452K	0.01%	645
2026 Q1	$1.85M	Buy	+24,051	New	+$1.88M	0.02%	589
2020 Q3	–	Sell	-1,036	Closed	-$34K	–	1000
2020 Q2	$34K	Buy	1,036 +333	+47%	+$11.9K	﹤0.01%	1076
2020 Q1	$29K	Buy	703 +144	+26%	+$7.66K	﹤0.01%	1070
2019 Q4	$34K	Buy	559 +44	+9%	+$2.92K	﹤0.01%	1071
2019 Q3	$38K	Buy	515 +183	+55%	+$13.7K	﹤0.01%	1080
2019 Q2	$27K	Sell	332 -62	-16%	-$4.41K	﹤0.01%	1089
2019 Q1	$28K	Buy	394 +48	+14%	+$2.82K	﹤0.01%	1102
2018 Q4	$16K	Sell	346 -58	-14%	-$3.04K	﹤0.01%	1124
2018 Q3	$23K	Buy	+404	New	+$24.7K	﹤0.01%	1140

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's ANIP Position: Q2 2026 in Review

Royce & Associates reduced its ANI Pharmaceuticals (ANIP) stake by 23% in Q2 2026, selling an estimated $452K and leaving 18,416 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #645.

Royce & Associates first reported a position in ANIP in Q3 2018 and has held it in 10 quarters since. The position peaked at $1.85M in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Royce & Associates held 18,416 shares of ANI Pharmaceuticals worth $1.52M as of Q2 2026.
Royce & Associates sold 5,635 ANI Pharmaceuticals shares in Q2 2026, an estimated $452K.
ANI Pharmaceuticals made up 0.01% of Royce & Associates's portfolio in Q2 2026, its #645 holding.
Royce & Associates first reported a position in ANI Pharmaceuticals in Q3 2018 and has held it in 10 quarters since.
Royce & Associates's ANI Pharmaceuticals position peaked at $1.85M in Q1 2026.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.